Fractional FLOw Reserve In Cardiovascular DiseAses

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04597489

Acronym

FLORIDA

Enrollment

64045

Registered

2020-10-22

Start date

2019-12-01

Completion date

2020-03-02

Last updated

2020-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome, Coronary Artery Disease

Brief summary

The FLORIDA (Fractional FLOw Reserve In cardiovascular DiseAses) study sought to investigate outcomes of FFR-guided versus angiography-guided treatment strategies in a large, real-world cohort.

Detailed description

The objective of the FLORIDA study was to investigate mortality outcomes of FFR-guided versus angiography-guided treatment strategies in a large, real-world patient cohort, including patients with different stages of coronary artery disease as well as patients with acute coronary syndrome (ACS). All patients were followed for a period of 3 years after the index date. The analysis period extended from the individual index date to the date of death or the end of the 3-year follow-up period. Patients were matched for sex, presence of acute coronary syndrome, age ± 5 years, and propensity scores estimated with logistic regression based on 72 variables , with each FFR patient matched to the closest angiography-only patient

Interventions

PROCEDUREFractional flow reserve

Patients were stratified into the FFR group if a coronary angiography with adjunctive FFR measurement was performed during the index hospitalization.

PROCEDUREAngiography-only

Patients were stratified into the angiography-only group if a coronary angiography without adjunctive FFR measurement was performed.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* At least one inpatient coronary angiography for suspected coronary artery disease between January 2014 and December 2015.

Exclusion criteria

* Loss to follow-up of other reasons than death (i.e. change of insurance)

Design outcomes

Primary

Measure	Time frame	Description
All-cause mortality	36 months	All patients were followed for a period of 3 years after the index date. The analysis period extended from the individual index date to the date of death or the end of the 3-year follow-up period. The primary endpoint was mortality at 3 years, prospectively assessed at a quarterly basis.

Secondary

Measure	Time frame	Description
All-cause mortality	12 months	Prospectively assessed at a quarterly basis.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026